IT Leaders May Underestimate the Risk of Shadow SaaS, Finds New Snow Software Survey
17.11.2022 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today unveiled new data highlighting the challenges facing IT leaders due to expanded software as a service (SaaS) usage. While a huge majority of IT leaders (96%) indicated they were ‘confident or very confident’ in their organization’s SaaS security measures, the top challenge for leaders managing SaaS was ‘employees adding new SaaS applications without notifying IT,’ suggesting that leaders may underestimate the importance of visibility in security.
According to IDC, SaaS is the top source for cloud spend in 2022, accounting for $177.8 billion of the market. In the new Snow survey examining the state of SaaS management, which surveyed 1,000 IT leaders from large organizations of 500+ employees in the United States and United Kingdom, 44% said ‘employees adding new SaaS applications without notifying IT’ is their top challenge to managing SaaS applications at their organization, closely followed by managing SaaS security (42%). When asked why these issues were so challenging, IT leaders indicated the impact to other IT programs (47%), organizational dynamics (38%), lack of time and resources (37%) and lack of visibility (36%).
“Post-pandemic IT teams are seeing a large increase in SaaS applications procured without the knowledge of IT,” said Becky Trevino, Executive Vice President of Products at Snow. “Amid increasing cybersecurity risks and mounting pressure to cut costs, IT leaders realize they need to better govern unknown and unsanctioned SaaS usage. CIOs are ultimately responsible for the security and management of SaaS applications regardless of where they are procured, and to do this effectively IT needs complete visibility into what it is they need to secure.”
Views on budget and security ownership depends on your leadership level
Cybersecurity is a major focus for IT decision-makers right now, particularly as business leaders navigate market uncertainty and plan 2023 budgets in anticipation of a recession. However, ownership is not clear among IT leaders, which can put organizations at risk for elevated costs and gaps in security.
- IT leaders ranked ‘managing the security of SaaS applications’ as the #1 most important issue to managing SaaS applications at their organization, followed by ‘identifying usage of all SaaS applications within our organization.’
- Ninety-six percent of those surveyed reported feeling ‘confident’ or ‘very confident’ in their organization’s SaaS security measures.
- According to the survey, SaaS purchasing power and IT/security responsibility rests firmly within two groups: CIOs/IT leadership and IT asset management (ITAM) or software asset management (SAM) teams.
- Senior leaders (41% of vice presidents, 45% of sr. vice presidents and 52% of C-level executives) look to the CIO and/or IT leadership to take responsibility for SaaS purchasing and security issues over other departments and roles, while more mid-level management (50% of managers and 44% of directors) put the onus of SaaS management and security on peers within ITAM/SAM.
- Forty-eight percent of IT leaders surveyed said that if budget, resources and time were not a factor, they’d like to pivot all SaaS application spending to IT to address SaaS sprawl.
Economic uncertainty is elevating cost concerns among IT leaders – though it’s not the top priority
Market conditions are driving increased scrutiny across all areas of cost in most organizations and optimizing spend while eliminating waste is an ongoing priority for IT teams. However, of those surveyed, IT leaders are currently more focused on cybersecurity of SaaS applications than costs.
- Despite continued uncertainty across the global markets, reining in the total cost of SaaS applications was ranked 5th on respondents’ priorities.
- If global uncertainty persists, more than three quarters of all respondents (77%) believe IT spend will decrease by as much as 50% to 75%.
- If IT spending decreases, IT leaders believe that the two core areas impacted will be IT staffing (20%) and strategic IT initiatives or programs (19%).
For more information about Snow’s latest survey, please visit: https://www.snowsoftware.com/blog/survey-anxiety-over-saas-security-plagues-it-leaders/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005232/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Donatell
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
